203 related articles for article (PubMed ID: 28736929)
1. Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.
Li P; Hu T; Yu X; Chahin S; Dahodwala N; Blum M; Pettit AR; Doshi JA
Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):2735-2757. PubMed ID: 28736929
[TBL] [Abstract][Full Text] [Related]
2. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
3. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
4. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
5. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
6. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
[TBL] [Abstract][Full Text] [Related]
7. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
8. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
Hartung DM; Johnston KA; McGregor JC; Bourdette DN
Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
[TBL] [Abstract][Full Text] [Related]
9. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
Tseng CW; Dudley RA; Chen R; Walensky RP
JAMA Netw Open; 2020 Apr; 3(4):e202739. PubMed ID: 32286656
[TBL] [Abstract][Full Text] [Related]
10. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
Stuart B; Hendrick FB; Xu J; Dougherty JS
Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
[TBL] [Abstract][Full Text] [Related]
11. Responses to Medicare drug costs among near-poor versus subsidized beneficiaries.
Fung V; Reed M; Price M; Brand R; Dow WH; Newhouse JP; Hsu J
Health Serv Res; 2013 Oct; 48(5):1653-68. PubMed ID: 23663197
[TBL] [Abstract][Full Text] [Related]
12. Consumer cost sharing and use of biopharmaceuticals for rheumatoid arthritis.
Robinson JC
Am J Manag Care; 2013 Jun; 19(6):e205-13. PubMed ID: 23844749
[TBL] [Abstract][Full Text] [Related]
13. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
Karaca-Mandic P; Joyce GF; Goldman DP; Laouri M
Health Serv Res; 2010 Oct; 45(5 Pt 1):1227-50. PubMed ID: 20831715
[TBL] [Abstract][Full Text] [Related]
14. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.
Doshi JA; Li P; Ladage VP; Pettit AR; Taylor EA
Am J Manag Care; 2016 Mar; 22(3):188-97. PubMed ID: 27023024
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries.
Kale HP; Patel AM; Carroll NV
J Manag Care Spec Pharm; 2018 Apr; 24(4):317-326. PubMed ID: 29578855
[TBL] [Abstract][Full Text] [Related]
16. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
17. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
18. Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.
Li P; Schwartz JS; Doshi JA
J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27836822
[TBL] [Abstract][Full Text] [Related]
19. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
20. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]